Pulse Health Successfully Closes Series “A” Round
Free Radical Measurement and Management Systems Scheduled for Release in 2008
PORTLAND, Ore.--(BUSINESS WIRE)--Pulse Health, the leader in helping consumers measure their health status through Exhaled Breath Condensate (EBC), today announced it has secured $2.15M in Series A financing. A mix of angel investors from California, Washington and Oregon joined to complete the round. Pulse Health intends to use the funds towards marketing its first suite of products that target the antioxidant supplement channel, as well as funding future product development efforts.
“The key to any healthy lifestyle is to be well informed about the invisible forces at work in our bodies”
Accelerating EBC Scientific Technology
Pulse has invented a method to instantly measure health markers through a simple breath test. Pulse’s flagship product is a handheld device that detects free radicals through a colorimetric reaction, and reactions are measured using a consumer-accessible spectroscope. Pulse’s method of reading the breath — known in the scientific community as EBC — represents a dramatic scientific advancement.
Health markers are almost universally measured through blood or urine tests. The emerging field of EBC measurement is increasingly studied as a noninvasive method of sampling the volatile compounds in the lungs, and is used by scientists to measure important biomarkers such as free radical levels. Global scientific leaders in EBC are hailing Pulse’s technology as ground breaking.
“The key to any healthy lifestyle is to be well informed about the invisible forces at work in our bodies,” said Chris Marsh, Pulse Health CEO. “Our investors, channel partners and the scientific community see great potential for Pulse Health to help consumers accurately measure and better manage their health and wellness. The support we’ve been able to generate at this early stage is exciting, and we should see commercial delivery of our first products in 2008 as a result.”
FRED – Measuring Free Radical Levels
Free radicals have long been associated with premature aging, stress and disease states. Pulse Health’s first product, the Free Radical Enzymatic Device (FRED), is, for the first time, capable of accurately measuring a person’s free radical levels outside of a laboratory environment. FRED is based on breathalyzer technology which has been in development at Pulse Health Labs for more than ten years.
The FRED System allows consumers to measure their metabolic baseline and guide them in a scientifically grounded health and wellness program. FRED tests will be able to help identify the effects of diet, stress, supplements, and everyday living based on free radical levels in individuals. Once armed with this critical information, consumers can create optimal, enhanced lifestyle programs built around stress-reduction techniques like a healthy diet, regular exercise and supplementation.
About Pulse Health
Founded in January 2006, Pulse Health is the leader in helping consumers measure their health status through Exhaled Breath Condensate (EBC) technology. Pulse’s initial product is the first consumer-based testing device and lifestyle program that instantly provides a free radical level baseline “number” using a simple noninvasive breath test. The privately held company has offices in Portland, OR; Philadelphia, PA; and Dallas, TX. For more information, see www.pulsehealthllc.com.